Pantoprazol Olikla (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Olikla, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and adolescents. GNH USA supplies Pantoprazol Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Olikla is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: supports healing of erosions caused by chronic acid exposure. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine disorder.

Pantoprazol Olikla may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools without blood. - Nausea: feeling of stomach upset. - Abdominal pain: cramping or discomfort. - Flatulence: excess gas. - Constipation: infrequent bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal blood test results. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

When prescribing Pantoprazol Olikla, consider the following safety measures: - Assess renal function: adjust use in severe renal impairment. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor long‑term therapy: evaluate need for continued use after 8‑12 weeks. - Pregnancy and lactation: use only if clearly needed. - Elderly patients: start with the lowest effective dose and monitor for fractures. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Olikla can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption. - Atazanavir: markedly decreased antiviral exposure. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: slight rise in serum levels. - Methotrexate: reduced renal clearance at high doses.